Shikhar Dhawan hit his first Indian Premier League century on Saturday as Delhi Capitals beat Chennai Super Kings to go back top of the table.
South African veteran AB de Villiers produced another blistering batting display meanwhile to take Royal Challengers Bangalore to victory over Rajasthan Royals and keep them in the playoff race.
India opener Dhawan batted through the Delhi innings as they chased Chennai's 179-4 in which Faf du Plessis made 58 and Ambati Rayudu an unbeaten 45.
Dhawan made 101 off 57 balls with 14 fours and one six but his partners Shreyas Iyer (23) and Marcus Stoinis (24) hit the boundaries that kept Delhi in the hunt. The surprise IPL contenders needed 15 off the last over and it was spin bowler Axar Patel who blasted three sixes to secure the win with a ball to spare.
"It feels very special," said the 34-year-old.
"At the start of the season also I was hitting the ball well but I wasn't converting those 20s into 50s. Once you do that, you take that confidence into the next game."
Delhi now lead reigning champions Mumbai Indians by two points while M.S. Dhoni's three-time winners Chennai have only three wins from nine games and are slumbering in sixth place in the eight team league. Mumbai play King's XI Punjab on Sunday.
In the opening game of the day, De Villiers hit an unbeaten 55 off 22 balls taking Bangalore from the verge of defeat -- needing 35 off 12 balls -- to a stunning seven wicket victory that kept Virat Kohli's side in fourth place and the final playoff spot.
The 36-year-old's latest power hitting left both sides in awe. He hit three straight sixes off the penultimate over by Jaydev Unadkat and overtook the target 177-6 with another six off Jofra Archer with two balls to spare. Bangalore made 179 for three with Kohli also making 43.
"I said to a few of the Rajasthan boys, I know you lost but sometimes it doesn't matter which side you're on, you can only go wow," said de Villiers' South African teammate Chris Morris.
India coach Ravi Shastri said this week that de Villiers should come out of his international retirement. After a 55 off 24 balls in a win over Mumbai and a devastating 73 off 33 balls against Kolkata, de Villiers now has the IPL's best strike rate and only Sanju Samson is up with his 19 sixes.
De Villiers said he was always "very nervous" going into such a run chase. "I try to hide it. I get very stressed. I'm proud of my performances. Want to perform for my team, have an impact to win games."
Bangalore coach Simon Katich called de Villiers a "freak" but knows he will need more sixes from the South African if the team are to win their first IPL title.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.